Patients were enrolled in this trial on the basis of the results of circulating cell-free tumor DNA (ctDNA) testing, either by digital PCR or targeted sequencing.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Currently, fulvestrant plus palbociclib is approved by the FDA in the metastatic breast cancer setting only following disease progression on endocrine therapy.
This phase 3 study compared endocrine therapy with or without abemaciclib in patients with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer.
There was no benefit to adding palbociclib to adjuvant endocrine therapy for treatment of early HR+, HER2- breast cancer vs endocrine therapy alone, according to a results from PALLAS.
Neoadjuvant atezolizumab plus standard-of-care chemotherapy improved the pCR rate among women with early TNBC, regardless of PD-L1 positivity.
In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
When should women begin getting mammograms? Guidance can vary based on an individual’s family history or other high-risk identifiers, but physicians advise that women get screened for breast cancer consistently by at least age 50. However, a recent study out of the United Kingdom suggests that starting breast cancer screenings earlier could have a large…
Findings showed atezolizumab in combination with paclitaxel did not meet statistical significance for progression free survival and also demonstrated a negative trend in overall survival.
The assay may play a role in determining use of other treatments like PARP inhibitors.
